A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
NCT07037758
This study is recruiting at 12 US sites in 11 states, according to its ClinicalTrials.gov record last updated .
Summary
The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248. The primary objective for dose exploration only is to determine the recommended dose for expansion and/or maximum tolerated combination dose (MTCD) of AB248 in combination with tarlatamab.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Extensive Stage Small Cell Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Amgen
- Last updated on ClinicalTrials.gov
- September 25, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- University of Southern California, Norris Comprehensive Cancer Center · Los Angeles, CA
Florida · 1
- Moffitt Cancer Center · Tampa, FL
Georgia · 1
- Emory University · Atlanta, GA
Kentucky · 1
- Norton Cancer Institute - Downtown · Louisville, KY
Massachusetts · 1
- Dana-Farber Cancer Institute · Boston, MA
Missouri · 1
- Siteman Cancer Center · St Louis, MO
New York · 1
- Memorial Sloan Kettering Cancer Center · New York, NY
Pennsylvania · 2
- Sidney Kimmel Cancer Center · Philadelphia, PA
- Allegheny General Hospital · Pittsburgh, PA
South Dakota · 1
- Avera Cancer Institute · Sioux Falls, SD
Tennessee · 1
- Baptist Cancer Center · Memphis, TN
Washington · 1
- Swedish Cancer Institute Medical Oncology · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.